New MRI technique could reveal Brain's electrical secrets in tumor patients
NCT ID NCT06470711
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Mayo Clinic study uses special MRI scans to map electrical activity in the brain. Researchers will compare healthy volunteers and people with a type of brain tumor called glioma. The goal is to improve how doctors diagnose and understand brain conditions.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could lead to better imaging methods to understand brain electrical activity, potentially improving diagnosis for brain tumor patients.
- What could go wrong
- This is an early observational study, not a treatment trial. It may not directly benefit participants or lead to immediate clinical changes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALIGNANT GLIOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Mayo Clinic in Arizona
RECRUITINGScottsdale, Arizona, 85259, United States
Contact Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Spinal fluid DNA test could personalize brain cancer therapy
- Experimental vaccine aims to rally immune system against recurrent brain cancer
- Immunotherapy drug nivolumab tested in young brain cancer patients
- Brain Tumor's hidden electrical signals could reveal its weaknesses
- New hope for aggressive brain tumors? early trial combines two targeted drugs
- Supercharged immune cells take on deadly brain tumors